Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10353 in Major Depressive Disorder (Phase II, China)
CTR20231965Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10353 in major depressive disorder (MDD), sponsored by Hengrui Therapeutics. Started Jul 2023; status: completed.
02
Drugs
HS-10353
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20231965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231965.